Novartis' Scemblix (asciminib) Receives the US FDA's Approval for the Treatment of Chronic Myeloid Leukemia
Shots:
- The approval is based on P-III ASCEMBL & P-I study that evaluates Scemblix in patients with Ph+ CML-CP with T315I mutation who had experienced resistance or intolerance to two TKIs
- The P-III ASCEMBL trial showed an MMR rate (25% vs 13%) @24wks. & patients who discontinued treatment due to AEs (7% vs 25%). An additional P-I data in patients with CML with T315I mutation support the US FDAs approval for 2nd indication in this patient population
- Scemblix is the 1st FDA-approved CML treatment that binds to ABL myristoyl pocket & has received the US FDA's accelerated & full approval for Ph+ CML-CP. The company has initiated regulatory submission for Scemblix in multiple countries globally
Ref: Novartis | Image: Novartis
Click here to read the full press release
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com